Glutaminyl Cyclase, Diseases, and Development of Glutaminyl
Por um escritor misterioso
Descrição
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study, Alzheimer's Research & Therapy
IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminyl cyclase isoenzymes
PDF) Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients
Schematic drawing of QC inhibitor approach. pGlu-Aβ
Some benzimidazole-based Glutaminyl Cyclase Inhibitors.
The First Potent Inhibitors for Human Glutaminyl Cyclase: Synthesis and Structure−Activity Relationship
PDF) Preparation of imidazolyl thiourea derivs. as glutaminyl cyclase inhibitors for treating cancer, nervous system disorders, and other diseases
Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology
Frontiers Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease
Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design - ScienceDirect
Computational Methods for the Design and Development of Glutaminyl Cyclase Inhibitors in Alzheimer's Disease
An overview of glutaminyl cyclase inhibitors for Alzheimer's disease
Computational Methods for the Design and Development of Glutaminyl Cyclase Inhibitors in Alzheimer's Disease
de
por adulto (o preço varia de acordo com o tamanho do grupo)